Persistent endometrial dysfunction after fertility-sparing treatment for endometrial carcinoma: insights…

StudyFrontiers in oncology· 2026

Persistent endometrial dysfunction after fertility-sparing treatment for endometrial carcinoma: insights from donor oocyte cycles.

Pierfrancesco Greco, Ermanno Greco, Maria Teresa Varricchio … Flavia Costanzi

Reproductive Medicine & FertilityStudyPrognosisQ2IF 3.1

Live birth rate after donor-egg IVF was low despite excellent embryo quality

Persistent endometrial dysfunction after fertility-sparing treatment for endometrial carcinoma: insights from donor oocyte cycles.

Pierfrancesco Greco … Flavia Costanzi

Frontiers in oncology · 2026

Background

Fertility-sparing treatment (fertility-sparing treatment) is an accepted option for selected women with endometrial carcinoma (endometrial carcinoma) or atypical endometrial hyperplasia (atypical endometrial hyperplasia) wishing to preserve fertility.

Methods

This retrospective case series included women aged ≥40 years with histologically confirmed Endometrioid endometrial carcinoma (endometrial carcinoma) or atypical endometrial hyperplasia who achieved complete response after fertility-sparing treatment and subsequently underwent blastocyst transfer through oocyte donation.

Results

fewer than 1 in 5 embryo transfers led to a live birth

18.5%

Per embryo transfer

31.2%

Per patient

More results

Sixteen patients underwent 27 embryo transfer cycles.

Median age at first transfer was 45.5 years.

Embryological outcomes were excellent, with a 96.8% oocyte survival rate and 80.4% top-quality blastocysts.

Patients with disease recurrence showed lower live birth rates than those without recurrence.

“

Conclusion · 1 of 2

Women aged ≥40 years undergoing oocyte donation after fertility-sparing treatment for endometrial carcinoma or atypical endometrial hyperplasia experience reduced reproductive success despite optimal embryo quality.

Conclusion · 2 of 2

These findings are consistent with the hypothesis of persistent endometrial dysfunction after fertility-sparing treatment and highlight the need for improved assessment of endometrial receptivity and timely integration of assisted reproductive treatment following complete response.

Persistent endometrial dysfunction after fertility-sparing treatment for endometrial carcinoma: insights from donor oocyte cycles.

Persistent endometrial dysfunction after fertility-sparing treatment for endometrial carcinoma: insights from donor oocyte cycles.

Related papers